Navigation Links
Another way to grow blood vessels
Date:2/20/2008

BOSTONResearchers at Dana-Farber Cancer Institute have found a previously unknown molecular pathway in mice that spurs the growth of new blood vessels when body parts are jeopardized by poor circulation.

At present, their observation adds to the understanding of blood vessel formation. In the future, though, the researchers suggest it is possible that the pathway could be manipulated as a means of treating heart and blood vessel diseases and cancer. The paper appears in the Feb. 21 issue of the journal Nature.

Bruce Spiegelman, PhD, and his colleagues at Dana-Farber discovered that PGC-1alpha a key metabolic regulatory molecule senses a dangerously low level of oxygen and nutrients when circulation is cut off and then triggers the formation of new blood vessels to re-supply the oxygen-starved area a process known as angiogenesis.

A similar response to hypoxia, or oxygen deprivation, has been observed before. The response is regulated by a group of proteins known as Hypoxia Inducible Factors (HIF) that detect hypoxia and activate the production of VEGF (vascular endothelial growth factor). VEGF, in turn, stimulates angiogenesis.

The newly discovered pathway provides an independent way of getting there, says Spiegelman, who is also a professor of cell biology at Harvard Medical School. Along with lead author Zoltan Arany, MD, PhD, and colleagues, Spiegelman found that HIF was completely left out of the loop when PGC-1alpha accomplished the same feat in single cells and in live mice using a different regulator, known as ERR-alpha (estrogen-related receptor-alpha).

When the scientists knocked out the activity of PGC-1 alpha (which was first identified in the Spiegelman lab) in cells and live mice, the hypoxia-induced response and angiogenesis were sharply decreased.

We were surprised to find this novel mechanism, comments Spiegelman.

It was apparently there all along, adds Arany. That means there is now
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies another strategy for normalizing tumor blood supply
2. Another Study Finds No Link Between MMR Vaccine and Autism
3. Will This President Never Learn? Another Budget -- Another Increase to Ineffective Abstinence-Only Programs
4. Fi-Med Management, Inc. Acquires California and Utah-based Mediplete, Looks Ahead to Another Year of Growth
5. Another Study Links Western Diet to Heart, Health Risks
6. 10 Great Ways for Teens to Stay Fit - from One Teen to Another
7. Teen Pregnancy Epidemic Another Reason for Women to Carry Condoms. Just in Case, Inc. Announces 10,000 Chic Condom Compact Give-Away to Womens Non-Profits Nationwide.
8. Another smart cancer drug can have toxic effects on the heart
9. FDA Sunscreen Labeling Decision Delayed Another Month, Leading U.S. Physician to Say, Enough Is Enough
10. Another Medtronic Sprint Fidelis Lead Lawsuit is Filed in Federal District Court
11. Portico(TM) Systems Charts Another Period of Rapid Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014 Acute coronary syndrome (ACS) ... healthcare costs, frequent recurrences and hospitalizations, and high ... ACS incidence increases with age and will be ... population increases around the world. ACS is classified ... heart muscle damage inferred from a person’s symptoms, ...
(Date:7/14/2014)... 14, 2014 Georgia State University ... groups under the fifth round of its Second ... of research and academic performance. , The ... of top-notch faculty members to the university, with ... in areas of national significance. , “With the ...
(Date:7/14/2014)... through the bloodstream, homing in on a sheath ... and metastasize to other organs, scientists at The ... in Cancer Cell . , "This completely ... provides new potential avenues to predict and prevent ... M.D., professor of Gynecologic Oncology and Reproductive Medicine ...
(Date:7/14/2014)... look back on 40 years of the Glasgow Coma Scale ... and clinical practice, in a new Personal View published in ... Personal View is published on the 40th anniversary of the ... Since this seminal publication, the Glasgow Coma Scale has provided ... level, the clinical hallmark of acute brain injury. The scale ...
(Date:7/14/2014)... D.C., July 14, 2014 A recent study published ... of the American Academy of Child and Adolescent Psychiatry ... the age of onset criterion for diagnosis of attention-deficit/hyperactivity ... for ADHD, previously set at 7 in DSM-IV, has ... of onset is now set at 12, rather than ...
Breaking Medicine News(10 mins):Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 2Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 3Health News:Acute Coronary Syndrome (ACS) Incident Cases to Reach 1.47 million by 2023, Says a New Report Available at ReportsnReports.com 4Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 3Health News:MD Anderson researchers discover new route for ovarian cancer spread 2Health News:MD Anderson researchers discover new route for ovarian cancer spread 3
... a novel study on condom use with help from ,scientists, ... the significance of condom use in curtailing spread of AIDS. ... study on a request from Pope Benedict XVI. The cardinal ... abstinence from sex in the fight against AIDS. ...
... has been approved by the Food and Drug Administration ... cyanide poisoning//. The kit contains the drug hydroxocobalamin, intravenous ... enables emergency treatment for known or suspected cyanide poisoning. ... to emergencies including possible attacks by terrorists is enhanced. ...
... people seeking medical help because of illnesses related to alcohol ... few years//. ,Current official statistics show that ... treated for accidents and emergencies caused due to drunkenness ... for the same also have doubled, reported NHS since 1997, ...
... given rise not only to high expectations of treatment ... the German Research Foundation, Deutsche Forschungsgemeinschaft (DFG) issued its ... developed enormously. ,The second memorandum, which ... on Genetic Research, makes it clear that gene therapy ...
... research study finds that 95 percent of Americans have pre ... new as American men //and women as far back as ... disappointed that spending hundreds of millions of dollars advising young ... being wasted. One official disagreed and opined that even if ...
... ingredient of psychedelic mushrooms, also called magic mushrooms ... disorder (OCD), according to a study// by University ... substances like psilocybin, psilocin, or muscimol. ,The ... 1970, according to AP reports. ,The intent ...
Cached Medicine News:Health News:Gene Therapy for Hereditary Immunodeficiency Diseases 2
(Date:7/14/2014)... July 14, 2014  Mylan Inc. (NASDAQ: MYL ... agreement with Abbott (NYSE: ... non-U.S. developed markets specialty and branded generics business ("the ... will receive 105 million shares of the combined ... of $50.20 on Friday, July 11, 2014, representing an approximately ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... 11, 2010 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... Tuesday, November 16 at the American Heart Association (AHA) ... and chief executive officer of Thoratec, will be discussing ...
... 2010 Ardea Biosciences, Inc. (Nasdaq: RDEA ... trials of BAY 86-9766 (formerly known as RDEA119) will ... and Treatment of Cancer (EORTC) – National Cancer Institute ... on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. ...
Cached Medicine Technology:Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 3Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 4